Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Augment bone graft PMA

This article was originally published in The Gray Sheet

Executive Summary

Tissue healing and regeneration firm BioMimetic said it expects FDA to schedule an advisory panel later this year for Augment bone graft, following the firm's Feb. 17 submission of the third and final module of its PMA application for the synthetic graft. The module contains a comprehensive review of clinical data related to Augment, the firm states. The firm reported in October that Augment demonstrated noninferiority to autograft in hindfoot and ankle fusion surgery in the pivotal trial, but at least one investment analyst called the data "ambiguous" (1"The Gray Sheet" Oct. 19, 2009)

You may also be interested in...

BioMimetic Augment PMA Delayed Slightly As FDA Seeks Additional Data

FDA approval of BioMimetic Therapeutics' Augment synthetic bone graft will likely be delayed by several months after the agency recently requested 12-month follow-up data, the firm said

Research In Brief

Conflict-of-interest disclosure: Editorial in Oct. 15 New England Journal of Medicine outlines new disclosure requirements for study authors, which will be adopted by all members of the International Committee of Medical Journal Editors. Under the new 1disclosure form, authors are asked to divulge four types of information: associations with commercial entities that provided support for the work reported in the submitted manuscript; associations with entities that could be viewed as having an interest in the general area of the submitted manuscript; similar financial associations involving spouses or children under 18 years old; and non-financial associations that may be relevant to the submitted manuscript. Because the new disclosure form has only been "use tested" by ICMJE member journals and may need adjustments, Oct. 15 to April 10, 2010, will be considered a beta-testing period, the editorial says

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts